These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32131709)

  • 41. Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience.
    Torresan F; Cavedon E; Mian C; Iacobone M
    World J Surg; 2018 Feb; 42(2):367-375. PubMed ID: 29134313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term prognosis of medullary thyroid carcinoma.
    Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
    Salaun PY; Campion L; Bournaud C; Faivre-Chauvet A; Vuillez JP; Taieb D; Ansquer C; Rousseau C; Borson-Chazot F; Bardet S; Oudoux A; Cariou B; Mirallié E; Chang CH; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
    J Nucl Med; 2012 Aug; 53(8):1185-92. PubMed ID: 22743249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Different outcomes in sporadic versus familial medullary thyroid cancer.
    Saltiki K; Simeakis G; Anagnostou E; Zapanti E; Anastasiou E; Alevizaki M
    Head Neck; 2019 Jan; 41(1):154-161. PubMed ID: 30548085
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
    Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
    Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemoembolization for liver metastases from medullary thyroid carcinoma.
    Fromigué J; De Baere T; Baudin E; Dromain C; Leboulleux S; Schlumberger M
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2496-9. PubMed ID: 16608897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer.
    Sabra MM; Ghossein R; Tuttle RM
    Thyroid; 2016 Apr; 26(4):518-24. PubMed ID: 26872102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology.
    Vogel T; Wendler J; Frank-Raue K; Kreissl MC; Spitzweg C; Fassnacht M; Raue F; Kroiss M
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32072159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic variables and calcitonin in medullary thyroid cancer.
    Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
    Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Smoldering medullary thyroid carcinoma liver metastasis 37 years after resection of an organ-confined tumor.
    Waters KM; Ali SZ; Erozan YS; Olson MT
    Diagn Cytopathol; 2015 Jan; 43(1):45-8. PubMed ID: 24550155
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.
    Valenciaga A; Grubbs EG; Porter K; Wakely PE; Williams MD; Cote GJ; Vasko VV; Saji M; Ringel MD
    Thyroid; 2017 Dec; 27(12):1523-1533. PubMed ID: 29105562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
    Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
    J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
    Papapetrou PD; Polymeris A
    Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic utility of PET/CT with
    Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
    Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
    J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.
    Ho AS; Wang L; Palmer FL; Yu C; Toset A; Patel S; Kattan MW; Tuttle RM; Ganly I
    Ann Surg Oncol; 2015 Aug; 22(8):2700-6. PubMed ID: 25366585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Postoperative external beam radiotherapy for medullary thyroid carcinoma with high risk of locoregional relapse].
    Compagnon F; Zerdoud S; Rives M; Laprie A; Sarini J; Grunenwald S; Chaltiel L; Graff P
    Cancer Radiother; 2016 Jul; 20(5):362-9. PubMed ID: 27396902
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.
    Kendler DB; Araújo ML; Alencar R; de Souza Accioly MT; Bulzico DA; de Noronha Pessoa CC; Accioly FA; de Farias TP; Lopes FPPL; Corbo R; Vaisman M; Vaisman F
    Endocrine; 2017 Dec; 58(3):474-480. PubMed ID: 28948577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.